Literature DB >> 20597945

The management of mucous membrane pemphigoid and pemphigus.

Richelle M Knudson1, Amer N Kalaaji, Alison J Bruce.   

Abstract

Mucous membrane pemphigoid and pemphigus vulgaris are autoimmune blistering disorders in which many similar drugs and therapeutic strategies are utilized. In general, localized disease can be treated with topical agents. In contrast, patients with more severe and progressive disease usually require a combination of systemic corticosteroids and immunosuppressive medications. Oral corticosteroids, adjuvant immunosuppressive agents, antibiotics such as dapsone and immunomodulatory procedures like intravenous immunoglobulin are the main therapeutic agents used in treating these two disorders. Much of the morbidity and mortality associated with these disorders are related to the sites involved and to the drugs used for therapy. Treatment should be individualized based on severity, extent, and rate of progression of disease, comorbidities, and age of the patient. Serum levels of specific autoantibodies and indirect immunofluorescence titers, in certain cases, can be used to monitor response to therapy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20597945     DOI: 10.1111/j.1529-8019.2010.01323.x

Source DB:  PubMed          Journal:  Dermatol Ther        ISSN: 1396-0296            Impact factor:   2.851


  10 in total

Review 1.  Dapsone in dermatology and beyond.

Authors:  Gottfried Wozel; Christian Blasum
Journal:  Arch Dermatol Res       Date:  2013-12-06       Impact factor: 3.017

2.  Anti-BP180-type mucous membrane pemphigoid: report of two cases.

Authors:  Mayumi Wada; Jun Sato; Masanobu Shindoh; Hideyuki Ujiie; Ken Natsuga; Wataru Nishie; Hiroshi Shimizu; Yoshimasa Kitagawa
Journal:  Odontology       Date:  2014-10-30       Impact factor: 2.634

3.  Monoclonal anti-CD20 Antibody Therapy in Cicatrical Pemphigoid with Oral and Hypopharyngeal Involvement and Related Conditions.

Authors:  Uwe Wollina; Friedemann Pabst; Heidrun Kuss; Michaela Tilp; Juliane Runge
Journal:  J Clin Aesthet Dermatol       Date:  2013-05

4.  Double-blind placebo-controlled trial of dapsone in antihistamine refractory chronic idiopathic urticaria.

Authors:  Matt Morgan; Andrew Cooke; Laura Rogers; Beverley Adams-Huet; David A Khan
Journal:  J Allergy Clin Immunol Pract       Date:  2014 Sep-Oct

5.  Pemphigus vulgaris: a multidisciplinary approach to management.

Authors:  Christopher Vinall; Lucy Stevens; Paul McArdle
Journal:  BMJ Case Rep       Date:  2013-12-16

6.  Oral mucocutaneous lesions - a comparative clinicopathological and immunofluorescence study.

Authors:  Annasamy Rameshkumar; Alex Kumaranthara Varghese; Thayalan Dineshkumar; Shaheen Ahmed; Janaki Venkatramani; G Sugirtharaj
Journal:  J Int Oral Health       Date:  2015-03

Review 7.  The role of intravenous immunoglobulin in treatment of mucous membrane pemphigoid: A review of literature.

Authors:  Soheil Tavakolpour
Journal:  J Res Med Sci       Date:  2016-06-14       Impact factor: 1.852

8.  Oral mucous membrane pemphigoid - Two case reports with varied clinical presentation.

Authors:  Sreedevi Dharman; Arvind Muthukrishnan
Journal:  J Indian Soc Periodontol       Date:  2016 Nov-Dec

9.  Gastrointestinal cytomegalovirus disease in a patient with pemphigus vulgaris treated with corticosteroid and mycophenolate mofetil.

Authors:  Luiza Barbosa Oliveira; Celina Wakisaka Maruta; Denise Miyamoto; Fernanda Aburesi Salvadori; Claudia Giuli Santi; Valeria Aoki; Amaro Nunes Duarte-Neto
Journal:  Autops Case Rep       Date:  2017-03-30

Review 10.  Anti-inflammatory and Immunomodulatory Effects of Antibiotics and Their Use in Dermatology.

Authors:  Swetalina Pradhan; Bhushan Madke; Poonam Kabra; Adarsh Lata Singh
Journal:  Indian J Dermatol       Date:  2016 Sep-Oct       Impact factor: 1.494

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.